These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

938 related items for PubMed ID: 21241234

  • 1. Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition.
    Alfie J, Aparicio LS, Waisman GD.
    Rev Recent Clin Trials; 2011 May; 6(2):134-46. PubMed ID: 21241234
    [Abstract] [Full Text] [Related]

  • 2. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
    Werner C, Pöss J, Böhm M.
    Drugs; 2010 Jul 09; 70(10):1215-30. PubMed ID: 20568830
    [Abstract] [Full Text] [Related]

  • 3. The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis.
    Whitlock R, Leon SJ, Manacsa H, Askin N, Rigatto C, Fatoba ST, Farag YMK, Tangri N.
    Nephrol Dial Transplant; 2023 Oct 31; 38(11):2503-2516. PubMed ID: 37309038
    [Abstract] [Full Text] [Related]

  • 4. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
    Horký K.
    Vnitr Lek; 2010 Feb 31; 56(2):120-6. PubMed ID: 20329582
    [Abstract] [Full Text] [Related]

  • 5. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K.
    Vnitr Lek; 2007 Apr 31; 53(4):364-70. PubMed ID: 17578167
    [Abstract] [Full Text] [Related]

  • 6. Update on role of direct renin inhibitor in diabetic kidney disease.
    Dhakarwal P, Agrawal V, Kumar A, Goli KM, Agrawal V.
    Ren Fail; 2014 Jul 31; 36(6):963-9. PubMed ID: 24678880
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
    Feng Y, Huang R, Kavanagh J, Li L, Zeng X, Li Y, Fu P.
    Am J Cardiovasc Drugs; 2019 Jun 31; 19(3):259-286. PubMed ID: 30737754
    [Abstract] [Full Text] [Related]

  • 8. Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal disease.
    Slagman MC, Navis G, Laverman GD.
    Curr Opin Nephrol Hypertens; 2010 Mar 31; 19(2):140-52. PubMed ID: 20051849
    [Abstract] [Full Text] [Related]

  • 9. Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination.
    Cagnoni F, Njwe CA, Zaninelli A, Ricci AR, Daffra D, D'Ospina A, Preti P, Destro M.
    Vasc Health Risk Manag; 2010 Aug 09; 6():549-59. PubMed ID: 20730071
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep 09; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 15. Renal and cardio-protective effects of direct renin inhibition: a systematic literature review.
    Lambers Heerspink HJ, Perkovic V, de Zeeuw D.
    J Hypertens; 2009 Dec 09; 27(12):2321-31. PubMed ID: 19727007
    [Abstract] [Full Text] [Related]

  • 16. Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.
    Ferrario CM.
    Life Sci; 2010 Feb 27; 86(9-10):289-99. PubMed ID: 19958778
    [Abstract] [Full Text] [Related]

  • 17. Reducing cardiovascular risk by blockade of the renin-angiotensin-aldosterone system.
    Cohn JN.
    Adv Ther; 2007 Feb 27; 24(6):1290-304. PubMed ID: 18165212
    [Abstract] [Full Text] [Related]

  • 18. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES, Fernandes LAB, Giollo-Júnior LT, Uyemura JRR, Matarucco CSS, Landim MIP, Cosenso-Martin LN, Tácito LHB, Moreno H, Vilela-Martin JF, Yugar-Toledo JC.
    Trials; 2018 Feb 12; 19(1):101. PubMed ID: 29433578
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.